Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Research at ESMO Virtual Congress 2020 Highlights Significant Progress in Cancers with High Unmet Medical Need

Bristol Myers Squibb Research at ESMO Virtual Congress 2020 Highlights Significant Progress in Cancers with High Unmet Medical Need

Bristol-Myers Squibb: Here's How Defeating Cancer Pays Dividends

Bristol Myers (BMY) reported earnings 30 days ago. What's next for the stock?

Why Is Bristol Myers (BMY) Down 2.3% Since Last Earnings Report?

Bristol Myers Squibb (BMY) closed the most recent trading day at $59.95, moving -0.17% from the previous trading session.

Bristol Myers Squibb (BMY) Stock Moves -0.17%: What You Should Know

Bristol Myers' (BMY) Onureg becomes the first and only FDA-approved continued AML therapy for patients in remission.

Bristol Myers Gets FDA Approval for Oral AML Therapy Onureg

NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb to Participate in Citi’s 15th Annual BioPharma Virtual Conference

Bristol Myers Squibb to Participate in Citi’s 15th Annual BioPharma Virtual Conference

Onureg is aimed at treating a particularly aggressive form of the disease.

Bristol Myers Squibb Wins FDA Approval for Leukemia Drug

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--BMS Announces Interim Results from Long-Term Study Reinforcing Efficacy and Safety Profile of Zeposia in Patients with Relapsing Forms of MS

Bristol Myers Squibb Announces Interim Results from Long-Term Study Reinforcing Efficacy and Safety Profile of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis

AbbVie

Eli Lilly

Merck

Pfizer

If you had gone off the grid in early January with no communication and just came back, you would see all the market indexes making new highs, but the levels are close to when you left.

Why Dividend-Paying Big Drug Companies May Be the Best Stocks to Own Now

This pharmaceutical giant can reward investors in even the toughest times.

Got $1,000? Invest in This Rock-Solid Dividend Stock

Bristol-Myers still trades below 2020 pre-virus highs by nearly 10%.

Bristol-Myers Squibb: Too Cheap To Ignore

Shares of Bristol-Myers Squibb Co. (NYSE:BMY) are up roughly 5% since I thought that the stock deserved better than a single-digit price-earnings ratio.

Shares of Bristol-Myers Have Tremendous Potential

Bristol Myers' (BMY) phase III study evaluating Idhifa in patients with relapsed or refractory acute myeloid leukemia fails to meet the primary endpoint.

Bristol Myers' Idhifa Fails to Meet Goal in Leukemia Study

Bristol Myers stock has slipped this year. But the addition of Celgene has helped bolster the pharmaceutical company's sales.

Bristol Myers Is Launching A New MS Drug — But Is BMY Stock A Buy?

Bristol Myers (BMY) enters into an agreement to acquire privately-held Forbius in a bid to boost its pipeline of immunotherapies.

Bristol Myers to Buy Forbius to Boost Immunotherapy Pipeline

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #AML--Bristol Myers Squibb Provides Update on Phase 3 IDHENTIFY Trial in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Bristol Myers Squibb Provides Update on Phase 3 IDHENTIFY Trial in Patients with Relapsed or Refractory Acute Myeloid Leukemia

NEW YORK & MONTREAL--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta Asset to Portfolio

Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta Asset to Portfolio

The future is bright for this drugmaker and its shareholders. Just wait for the dip.

My Top Pharma Stock to Buy in the Next Market Crash

Bristol Myers (BMY) collaborates with Dragonfly Therapeutics, Inc. for its experimental immunotherapy program.

Bristol Myers & Dragonfly Team Up for Immunotherapy Program

Cigna

Immunomedics

Medtronic

With earnings reporting for the second quarter all but over, and the summer starting to wind down, many of the top companies we follow on Wall Street are making some changes to the lists of their high-conviction stock picks for clients.

BofA Securities Adds Medical Technology Giant to the US 1 List

Esperion Therapeutics

Sales of these recently launched products could make a big difference for the companies behind them.

3 New Drug Launches of 2020 -- and the Stocks That Could Win Big

Bristol-Myers Squibb: Celgene Effects Materializing

NEW YORK & WALTHAM, Mass.--(BUSINESS WIRE)---- $BMY--Dragonfly Therapeutics and Bristol Myers Squibb Announce Exclusive Global License for Dragonfly’s IL-12 Investigational Immunotherapy Program

Dragonfly Therapeutics and Bristol Myers Squibb Announce Exclusive Global License for Dragonfly’s IL-12 Investigational Immunotherapy Program

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb & Bristol Myers Squibb Foundation Commit $300 Million to Accelerate and Expand Health Equity and Diversity and Inclusion Efforts

Bristol Myers Squibb and the Bristol Myers Squibb Foundation Commit $300 Million to Accelerate and Expand Health Equity and Diversity and Inclusion Efforts

Bristol Myers Squibb on Tuesday reported positive Phase 3 test results for cancer drug Opdivo, one of its top products, sending BMY stock up to three-month highs near a possible buy point.
The post Bristol Myers Reports Cancer Drug Test Success; BMY Stock Nears Buy Point appeared first on Investor's Business Daily.

News for Bristol-Myers Stock (BMY)